Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Partners to target CNS compounds
February 2014
SHARING OPTIONS:

LEIDEN, The Netherlands—Brain drug development company to-BBB has initiated a collaboration agreement with Sun Moral International Ltd., a wholly owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., aimed at researching and developing innovative drugs for the treatment of central nervous system diseases. The companies will conduct feasibility studies using to-BBB’s G- Technology, which enables sustained release and enhanced brain delivery, on select drug compounds of Sihuan’s. Depending on the success of those studies, both companies look to begin a commercial license agreement for collaborative development of one or more of the compounds using G-Technology, with Sihuan pursuing product approval in China. Dr. Che FengSheng, CEO and chairman of Sihuan, said the company began this agreement “to tap the high unmet medical need of drug products with sustained delivery to the CNS.”
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.